Number of antibodies Number Of Antibodies Number Of Antibodies Less accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Liability from in-licensing agreements Liabilities From-In-Licensing Agreements Liabilities From-In-Licensing Agreements Investments Investment, Policy [Policy Text Block] Award Timing Predetermined Award Timing Predetermined [Flag] IPR&D Indefinite Lived Intangible Assets In Process Research and Development [Member] Information by major type or class of indefinite-lived intangible assets. In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process. Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Stock Based Compensation Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent Unrealized loss on available for sale securities, tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax Entity File Number Entity File Number Additional paid-in capital Additional Paid-in Capital [Member] Zymeworks Royalty Limited Partnership Zymeworks Royalty Limited Partnership [Member] Zymeworks Royalty Limited Partnership SR&ED Tax Credits Effective Income Tax Rate Reconciliation, Tax Credit, Amount Tabular List, Table Tabular List [Table Text Block] Recent accounting pronouncements adopted and Recent accounting pronouncements not yet adopted New Accounting Pronouncements, Policy [Policy Text Block] Finance lease liabilities: Finance Lease, Liability [Abstract] Operating lease right-of-use assets Deferred Tax Liabilities Operating lease right-of-use assets Deferred tax liabilities, operating lease right-of-use assets . Changes due to SR&ED and research credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Adjustment to Compensation: Adjustment to Compensation [Axis] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Tax credit carryforward, amount not subject to expiration Tax Credit Carryforward, Not Subject To Expiration Tax Credit Carryforward, Not Subject To Expiration Issuance of common stock upon vesting of restricted stock units ("RSUs") (note 10e) ("RSUs") (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Issuance of common stock through employee stock purchase plan (note 10f) (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Current income tax expense Current Income Tax Expense (Benefit) Adjustments to prior year Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount Adjustment to Compensation, Amount Adjustment to Compensation Amount Concentration risk, percentage Concentration Risk, Percentage Contractual maturity of three to four years: Debt Securities, Available-For-Sale Fiscal Year Maturity, Year One Through Four [Abstract] Debt Securities, Available-For-Sale Fiscal Year Maturity, Year One Through Four Stock-based compensation (note 10e) Share-Based Payment Arrangement, Noncash Expense Foreign Base Company Income Effective Income Tax Rate Reconciliation, FDII, Amount Share-based Payment Arrangement, Option Share-based Payment Arrangement, Option Share-Based Payment Arrangement, Option [Member] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Clinical Trial Expense Accruals Clinical Trial Expense Accruals [Policy Text Block] Clinical Trial Expense Accruals. Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Effective Income Tax Rate Reconciliation, Percent [Abstract] Effective Income Tax Rate Reconciliation, Percent [Abstract] Collaborative agreement expansion fee Collaborative Agreement Expansion Fee Collaborative agreement expansion fee. Merck Sharp & Dohme LLC (“Merck”) Merck Sharp & Dohme LLC [Member] Merck Sharp & Dohme LLC Total stockholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Debt Securities, Available-for-Sale [Table] Debt Securities, Available-for-Sale [Table] Insider Trading Policies and Procedures [Line Items] Schedule of Components of Property and Equipment Property, Plant and Equipment [Table Text Block] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Acquired In-Process Research and Development (IPR&D) and Definite-lived Intangible Assets Acquired In Process Research And Development And Definite Lived Intangible Assets [Policy Text Block] Acquired In Process Research And Development And Definite Lived Intangible Assets. Issuance of common stock in connection with At-The-Market ("ATM") sale (note 10a) (in shares) Stock Issued During Period, Shares, New Issues Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Description of payment terms Revenue, Performance Obligation, Description of Payment Terms ZW191 ZW191 [Member] ZW191 Cover [Abstract] Cover [Abstract] Cash and cash equivalents: Cash and Cash Equivalents, Fair Value Disclosure Maximum Maximum [Member] Exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Definite-lived intangible assets, useful life Finite-Lived Intangible Asset, Useful Life Intangible assets, net (note 8) Intangible assets, net Finite-Lived Intangible Assets, Net Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Future royalty percentage not to exceed threshold percentage of loan payable Future Royalty Percentage Not To Exceed Threshold Percentage Of Loan Payable Future Royalty Percentage Not To Exceed Threshold Percentage Of Loan Payable Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Derivative liability, classified stock options and ESPP Derivative Liability, Classified Stock Options and ESPP Derivative Liability, Classified Stock Options and ESPP Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Royalty payments on future global net sales (up to) Percentage of Royalty Rate Payments Percentage of royalty rate payments. Temporary Equity [Line Items] Temporary Equity [Line Items] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] ZW25 Agreement ZW25 Agreement [Member] ZW25 Agreement. Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Entity Shell Company Entity Shell Company Celgene Celgene [Member] Celgene. Statement of Stockholders' Equity [Abstract] Schedule of Cash Income Taxes Paid Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Class of warrant or right, pre-funded (in shares) Class of Warrant or Right, Pre-Funded Pre funded warrants issued in lieu of common shares to underwriters. Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Amounts paid or transferred to payables Contingent Consideration Liability Fair Value Disclosure, Transfers Contingent Consideration Liability Fair Value Disclosure, Transfers Long-term marketable securities (note 5) Debt Securities, Available-for-Sale, Excluding Accrued Interest, Noncurrent United States Income (Loss) from Continuing Operations before Income Taxes, Domestic Schedule of Stock-based Compensation Expense for Equity Classified Instruments Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Current portion of operating lease liability (note 14) Current portion Operating Lease, Liability, Current Document Fiscal Period Focus Document Fiscal Period Focus Weighted average remaining lease term: Weighted Average Remaining Lease Term [Abstract] Weighted Average Remaining Lease Term Award Timing Method Award Timing Method [Text Block] Furniture and fixtures Furniture and Fixtures [Member] Award Type [Axis] Award Type [Axis] Award Type [Axis] Deferred revenue (note 11) Contract with Customer, Liability, Noncurrent Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Purchases of common stock not settled Payments for Repurchase of Common Stock Not Settled Payments for Repurchase of Common Stock Not Settled Trading Symbol Trading Symbol Weighted average discount rate: Weighted Average Discount Rate [Abstract] Weighted Average Discount Rate Changes in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Accrued expenses Accrued Liabilities and Other Liabilities Entity Address, City or Town Entity Address, City or Town 4 to 5 years Lessee, Operating Lease, Liability, to be Paid, Rolling Year Five Number of agreements Number Of Agreements Number Of Agreements Intangible Assets Intangible Assets Disclosure [Text Block] Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Statement of Income Location, Balance [Domain] Statement of Income Location, Balance [Domain] Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Research period extension fee Research Period Extension Fee [Member] Research Period Extension Fee Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Number of programs discontinued Number Of Programs Discontinued Number Of Programs Discontinued Gross decreases due to settlements with taxing authorities Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Entity Emerging Growth Company Entity Emerging Growth Company Acquisition of intangible assets Payments to Acquire Intangible Assets Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Number of liability classified stock options outstanding (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Exchange of shares per the Redomiciliation (in shares) Temporary Equity, Stock Issued During Period, Shares, New Issues Temporary Equity, Stock Issued During Period, Shares, New Issues Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Beginning balance Ending balance Indefinite-Lived Intangible Assets (Excluding Goodwill) Net monetary assets denominated in foreign currency Net Monetary Assets Denominated In Foreign Currency Net Monetary Assets Denominated In Foreign Currency Research Milestone Research Milestone [Member] Research Milestone [Member] Common shares, outstanding (in shares) Common Stock, Shares, Outstanding Investments, cost Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One Through Four Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One Through Four Unrealized foreign exchange loss (gain) Unrealized Gain (Loss), Foreign Currency Transaction, before Tax Income tax payable (note 13) Accrued Income Taxes, Current Issuance of common stock on exercise of stock options (note 10e) Stock Issued During Period, Value, Stock Options Exercised Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Schedule of Finite-Lived Intangible Assets, Future Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Entity Address, Postal Zip Code Entity Address, Postal Zip Code Restatement Determination Date Restatement Determination Date Income tax (expense) recovery (note 13) Income tax (expense) recovery Income tax (expense) recovery, net Income Tax Expense (Benefit) Royalty Pharma Royalty Pharma [Member] Royalty Pharma Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Future royalty percentage sold Future Royalty Percentage Sold Future Royalty Percentage Sold Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Property and equipment Property, Plant and Equipment, Gross Stock Repurchases Stockholders' Equity, Policy [Policy Text Block] Accumulated Impairment Indefinite-lived Intangible Assets Accumulated Impairment [Roll Forward] Indefinite-lived Intangible Assets Accumulated Impairment Other Income and Expenses [Abstract] Other Income and Expenses [Abstract] Amortization and impairment of operating lease right-of-use assets Operating Lease, Right-of-Use Asset, Periodic Reduction Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] First Phase 2 Trial First Phase 2 Trial [Member] First Phase 2 Trial Proceeds from stock options exercised Proceeds from Stock Options Exercised Private placement (note 10a) Proceeds from Issuance of Private Placement Research Agreement Product Four Research Agreement Product Four [Member] Research Agreement Product Four Federal Income Tax Paid, Federal, after Refund Received All Trading Arrangements All Trading Arrangements [Member] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Remaining unamortized compensation expense, weighted-average period Weighted-average contractual term, vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Intangible assets Deferred Tax Assets, Goodwill and Intangible Assets Other Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Deferred tax liabilities: Deferred Tax Liabilities, Gross [Abstract] Schedule of Changes in Fair Value of the Company's Liability for Contingent Consideration Changes In Fair Value Of Contingent Consideration [Table Text Block] Changes In Fair Value Of Contingent Consideration [Table Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Change during the period Indefinite-Lived Intangible Assets Accumulated Amortization Indefinite-Lived Intangible Assets Accumulated Amortization Net cash used in operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Non-vested, beginning balance (in shares) Non-vested, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares Debt securities, available-for-sale, excluding accrued interest Marketable securities: Debt Securities, Available-for-Sale, Excluding Accrued Interest Purchase and retirement of common stock (10c) Treasury Stock, Retired, Cost Method, Amount 2025 Repurchase Program Repurchase Program, 2025 [Member] Repurchase Program, 2025 Property and equipment useful lives Property, Plant and Equipment, Useful Life Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Subsequent Event Subsequent Event [Member] Schedule of Estimated Fair Value of Stock Options Assumptions Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] PEO Total Compensation Amount PEO Total Compensation Amount Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Depreciation of property and equipment (note 7) Depreciation expense Depreciation Vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Money market funds Money Market Funds [Member] Weighted-average common stock outstanding: Weighted Average Number of Shares Outstanding, Basic [Abstract] Equity Components [Axis] Equity Components [Axis] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] First Phase 3 Trial First Phase 3 Trial [Member] First Phase 3 Trial Stock options Deferred Tax Assets Stock Options Deferred Tax Assets Stock Options Technology Access Fee Technology Service [Member] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Number of reportable segments Number of Reportable Segments Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Federal Tax Incentive Federal Tax Incentive [Member] federal tax incentive [Member] Debt securities, fair value Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, After Year Three Through Four Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, After Year Three Through Four Schedule of Operating Leased Assets [Table] Schedule of Operating Leased Assets [Table] Entity Address, State or Province Entity Address, State or Province Research licenses Research Licenses [Member] Research Licenses Impairment loss Operating Lease, Impairment Loss Total current liabilities Liabilities, Current Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] Individual: Individual [Axis] Income Tax Jurisdiction [Domain] Income Tax Jurisdiction [Domain] Royalty term Collaborative Arrangement, Royalty Term Collaborative Arrangement, Royalty Term Contractual maturity of one year or less: Debt Securities, Available-For-Sale Fiscal Year Maturity, Year One [Abstract] Debt Securities, Available-For-Sale Fiscal Year Maturity, Year One Accounting Changes and Error Corrections [Abstract] Accounting Changes and Error Corrections [Abstract] Document Annual Report Document Annual Report Research and development expense Research and Development Expense [Member] Collaborative arrangement, number of products Collaborative Arrangement, Number Of Products Collaborative Arrangement, Number Of Products Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Debt securities, fair value Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, After Year One Through Three Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, After Year One Through Three Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Research and development deductions and credits Deferred Tax Asset, In-Process Research and Development Entity Interactive Data Current Entity Interactive Data Current Deferred revenue Deferred Tax Assets, Deferred Income Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Aggregate intrinsic value exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Business Combination, Contingent Consideration, Type [Axis] Business Combination, Contingent Consideration, Type [Axis] Net operating loss carry forwards Deferred Tax Assets, Operating Loss Carryforwards Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] LEO Pharma Leo Pharma [Member] Leo Pharma. Merck Sharp and Dohme Research Ltd. Merck Sharp and Dohme Research Ltd. [Member] Merck sharp and dohme research ltd. Proceeds from collaboration agreement Payment Received On Collaboration Agreement Payment Received On Collaboration Agreement Acquired IPR&D, beginning balance Acquired IPR&D, ending balance Acquired In Process Research And Development Acquired in Process Research and Development. Schedule Of Accounting Policies [Table] Schedule Of Accounting Policies [Table] Schedule of accounting policies. Customer [Domain] Customer [Domain] Entity Central Index Key Entity Central Index Key PEO Name PEO Name Liability for Contingent Consideration Liability for Contingent Consideration [Member] Liability for contingent consideration. Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Accounts Receivable and Expected Credit Losses Accounts Receivable And Expected Credit Losses [Policy Text Block] Accounts Receivable And Expected Credit Losses Deferred revenue and other consideration (note 11) Contract liabilities Contract with Customer, Liability, Current Warrant exercise price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Exercise Price Award Exercise Price Entity Filer Category Entity Filer Category Class of Stock [Domain] Class of Stock [Domain] Valuation Allowance by Deferred Tax Asset [Axis] Valuation Allowance by Deferred Tax Asset [Axis] U.S. Federal statutory income tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Subsequent Event Type [Axis] Subsequent Event Type [Axis] Development Milestone Development Milestone [Member] Development milestone. Private placement for issuance of common stock (note 10a and 10d) (in shares) Stock Issued During Period, Shares, Private Placement Stock Issued During Period, Shares, Private Placement Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Three Collaborative arrangement, maximum regulatory milestone payments Collaborative Arrangement, Maximum Regulatory Milestone Payments Collaborative Arrangement, Maximum Regulatory Milestone Payments Finite-lived intangible assets, gross Finite-Lived Intangible Assets, Gross Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Schedule of Acquired Indefinite-lived Intangible Assets by Major Class [Table] Schedule of Acquired Indefinite-Lived Intangible Assets by Major Class [Table] Entity Address, Address Line Two Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Research and development expense Research and Development Expense Accumulated other comprehensive loss AOCI Attributable to Parent [Member] Debt securities, amortized cost Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, After Year Three Through Four Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, After Year Three Through Four Issuance of common stock upon exercise of pre-funded warrants (note 10d) (in shares) Issuance of common shares upon exercise of pre-funded warrants (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Issuance of common stock upon exercise of pre-funded warrants (note 10d) Stock Issued Research, Development, Commercial License Option Milestone Research And Development Regulatory And Sales Related Milestone [Member] Research and development regulatory and sales related milestone. Provincial tax rate differential Effective Income Tax Rate Reconciliation, Foreign Income Provincial Tax Rate Differential, Percent Effective Income Tax Rate Reconciliation, Foreign Income Provincial Tax Rate Differential, Percent Fair Value as of Grant Date Award Grant Date Fair Value Schedule of Other Income (Expense) Nonoperating Schedule of Other Nonoperating Income (Expense) [Table Text Block] Changes in unrecognized tax benefits Effective Income Tax Rate Reconciliation, Tax Contingency, Amount Salaries and benefits Labor and Related Expense Deferred Revenue Deferred Revenue [Member] Deferred Revenue Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Maximum milestone payments and tiered royalties Collaborative Arrangement, Maximum Milestone Payments and Tiered Royalties Collaborative Arrangement, Maximum Milestone Payments and Tiered Royalties Options forfeited and cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares Total operating expenses Costs and Expenses Nonvested award, cost not yet recognized, amount Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Royalty percentage earned from sales of product Royalty Percentage Earned From Product Sales Royalty percentage earned from product sales. Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Counterparty Name [Domain] Counterparty Name [Domain] Investments, All Other Investments [Abstract] Investments, All Other Investments [Abstract] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Weighted-average contractual term, outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Schedule of Accounts Payable and Accrued Liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration] Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration] Title Trading Arrangement, Individual Title Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Acquired IPR&D Indefinite-lived Intangible Assets Acquired [Roll Forward] Indefinite-lived Intangible Assets Acquired Recognition of deferred revenue Recognition of Deferred Revenue [Member] Recognition of Deferred Revenue Non-PEO NEO Non-PEO NEO [Member] Aggregate intrinsic value outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Issuance of common stock through employee stock purchase plan (note 10f) Stock Issued During Period, Value, Employee Stock Purchase Plan 3 to 4 years Lessee, Operating Lease, Liability, to be Paid, Rolling Year Four Research Agreement Product Two Research Agreement Product Two [Member] Research Agreement Product Two Sale of Stock [Axis] Sale of Stock [Axis] Beginning balance Ending balance Indefinite Lived Intangible Assets Impairment Indefinite Lived Intangible Assets Impairment Schedule of Repurchase Agreements Schedule of Repurchase Agreements [Table Text Block] Award Type [Domain] Award Type [Domain] Award Type [Domain] Equity Awards Adjustments Equity Awards Adjustments [Member] Leasehold improvements Leasehold Improvements [Member] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Effect of cross-border laws Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Percent Research Agreement Product Three Research Agreement Product Three [Member] Research Agreement Product Three Canada CANADA Compensation Amount Outstanding Recovery Compensation Amount Cross License Agreement Cross License Agreement [Member] Cross license agreement. Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Change In Clinical Trial Expense Accrual Change In Clinical Trial Expense Accrual [Member] Change In Clinical Trial Expense Accrual License and Collaboration License and Collaboration [Member] License and Collaboration MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Tax rate differential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Increase (decrease) in fair value of liability for contingent consideration Contingent Consideration Fair Value Adjustments Contingent consideration fair value adjustments. Non-vested, beginning balance (in dollars per share) Non-vested, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price Metastatic Castration-Resistant Prostate Cancer Metastatic Castration-Resistant Prostate Cancer [Member] Metastatic Castration-Resistant Prostate Cancer Change in fair value of contingent consideration liability (note 15) Change in contingent consideration Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease) Employee Stock Employee Stock [Member] Revenue: Revenues [Abstract] Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Number of additional antibodies Number Of Additional Antibodies Number Of Additional Antibodies Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Amount Due If Paid At Maturity Amount Due If Paid At Maturity [Member] Amount Due If Paid At Maturity Financial Instruments [Domain] Financial Instruments [Domain] Gross deferred tax liabilities Deferred Tax Liabilities, Gross Schedule of Carrying Value of IPR&D, Net of Impairment Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Royalties Royalty [Member] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Minimum Minimum [Member] Goods and services tax payable Sales and Excise Tax Payable, Current Company Selected Measure Name Company Selected Measure Name Number of renewal options Lessee, Operating Lease, Number Of Renewal Options Lessee, Operating Lease, Number Of Renewal Options Deferred tax assets liabilities before valuation allowance Deferred Tax Assets Liabilities Before Valuation Allowance Deferred tax assets (liabilities) before valuation allowance. Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Cash paid for measurement of operating lease liabilities Operating Lease, Payments Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Diluted Net Income (Loss) Available to Common Stockholders, Diluted Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Foreign Current Foreign Tax Expense (Benefit) Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Diluted (in shares) Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Segment Information Segment Reporting, Policy [Policy Text Block] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Entity Small Business Entity Small Business Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding State Current State and Local Tax Expense (Benefit) Document Transition Report Document Transition Report Underlying Securities Award Underlying Securities Amount ZW251 ZW251 [Member] ZW251 Equity Component [Domain] Equity Component [Domain] Document Period End Date Document Period End Date Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Income Taxes Income Tax Disclosure [Text Block] United Kingdom UNITED KINGDOM Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Commercial Sales Milestones Commercial Sales Milestones [Member] Commercial Sales Milestones [Member] Weighted-average contractual term, exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Average price paid per share ( in usd per share) Shares Acquired, Average Cost Per Share Document Type Document Type Outstanding at beginning of period (in shares) Outstanding, at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Level 3 Fair Value, Inputs, Level 3 [Member] Net Loss per Share Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name Product and Service [Axis] Product and Service [Axis] Office equipment Office Equipment [Member] Business Combination, Contingent Consideration, Type [Domain] Business Combination, Contingent Consideration, Type [Domain] Variable lease expense Variable Lease, Cost Adjustment for dilutive effect of liability classified stock options (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements, Liability Classified Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements, Liability Classified Research and development collaborations (note 11) Research and development collaborations Revenue from Contract with Customer, Excluding Assessed Tax Effect of Change in Accounting Estimate, Type [Domain] Effect of Change in Accounting Estimate, Type [Domain] Vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Total current assets Assets, Current Statistical Measurement [Axis] Statistical Measurement [Axis] Research Agreement Product One Member Research Agreement Product One Member [Member] Research Agreement Product One Member Share repurchase program, authorized amount Share Repurchase Program, Authorized, Amount Long-term prepaids and other assets Prepaid Expense and Other Assets, Noncurrent Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Disposal Group Name [Axis] Disposal Group Name [Axis] Accrued legal, professional fees and other Accrued Legal And Professional Fees, Current Accrued legal and professional fees, current. Laboratory equipment Laboratory Equipment [Member] PropertyPlantAndEquipmentByTypeAxis=zyme Option exercised intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Basic Net Income (Loss) Available to Common Stockholders, Basic Share Repurchase Program [Domain] Share Repurchase Program [Domain] Total other comprehensive income (loss) Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Current liabilities: Liabilities, Current [Abstract] Weighted- Average Contractual Term (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Business Combination and Goodwill Business Combinations And Goodwill [Policy Text Block] Business Combinations And Goodwill. Exchangeable shares Exchangeable Shares [Member] Exchangeable Shares Collaborative arrangement, maximum commercial milestone payments Collaborative Arrangement, Maximum Commercial Milestone Payments Collaborative Arrangement, Maximum Commercial Milestone Payments Research, Development and Commercial Milestones Research, Development and Commercial Milestones [Member] Research, development and commercial milestones member Level 1 Fair Value, Inputs, Level 1 [Member] Commercial Milestones Commercial Milestones [Member] Commercial milestones. Diluted (in dollars per share) Net loss per common share – diluted (in dollars per share) Earnings Per Share, Diluted BeOne Medicines Ltd. (previously known as BeiGene, Ltd.) (“BeOne”): BeOne Medicines Ltd. [Member] BeOne Medicines Ltd. Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current British Columbia BRITISH COLUMBIA Contractual maturity of one to three years: Debt Securities, Available-For-Sale Fiscal Year Maturity, Year One Through Three [Abstract] Debt Securities, Available-For-Sale Fiscal Year Maturity, Year One Through Three Number of common shares issued (in shares) Sale of Stock, Number of Shares Issued in Transaction State Income Tax Paid, State and Local, after Refund Received Auditor Location Auditor Location Termination fee Lessee, Operating Lease, Termination Fee Lessee, Operating Lease, Termination Fee Number of potential products to developed and commercialized Number of potential products developed and commercialized Number of potential products developed and commercialized. Domestic Tax Jurisdiction [Member] Domestic Tax Jurisdiction [Member] Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Adjustment for change in fair value of liability classified stock options Fair Value, Option, Adjustment For Change In Fair Value Of Liability Classified Stock Options Fair Value, Option, Adjustment For Change In Fair Value Of Liability Classified Stock Options Imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] Net cash paid during the year for income taxes Net cash paid during the year for income taxes Income Taxes Paid, Net Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Two Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Employee compensation and related accruals Employee-related Liabilities, Current Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Future operating lease payments Total operating lease payments Lessee, Operating Lease, Liability, to be Paid Unrealized income (loss) on available for sale securities, net of tax of nil (note 5) OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Canadian Dollar Under the New Option Stock Plan CAD Dollars Under The New Stock Option Plan [Member] CAD dollars under the new stock option plan. Expiration Date Trading Arrangement Expiration Date Options vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value Amount Due If Paid On Or Before December 31, 2033 Amount Due If Paid On Or Before December 31, 2033 [Member] Amount Due If Paid On Or Before December 31, 2033 Property and equipment, net (note 7) Property and equipment, net Property, Plant and Equipment, Net Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Accounts receivable Increase (Decrease) in Accounts Receivable Entity Current Reporting Status Entity Current Reporting Status Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Unamortized compensation expense related to unvested options Share Based Compensation By Share Based Payment Award Unamortized Compensation Expense Share based compensation by share based payment award unamortized compensation expense. Debt securities, amortized cost Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One U.S. Federal statutory income tax rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Bristol-Myers Squibb (“BMS”): Bristol-Myers Squibb [Member] Bristol-Myers Squibb Financial Instrument [Axis] Financial Instrument [Axis] Deferred tax assets: Deferred Tax Assets, Gross [Abstract] Items not involving cash: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Noncash Item [Abstract] Statement of Financial Position [Abstract] Executive Category: Executive Category [Axis] Canada, Dollars Canada, Dollars Stock options Deferred Tax Liabilities, Stock Options Deferred Tax Liabilities, Stock Options State & local income tax, net of federal income tax effect Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Total other income, net Other Operating Income (Expense), Net Current portion included in other current liabilities Finance Lease, Liability, Current Current Fiscal Year End Date Current Fiscal Year End Date Class of warrant or right, number of securities called by each warrant or right (in shares) Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Ireland IRELAND Expected average option term Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] ZW220 ZW220 [Member] ZW220 Delivery of Licenses, Initial Technology Transfer and BTC Data Transfer Delivery Of Licenses, Initial Technology Transfer And BTC Data Transfer [Member] Delivery Of Licenses, Initial Technology Transfer And BTC Data Transfer Weighted- average grant date fair value ($) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Number of shares available for grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Fair value of liability classified stock options Derivative Liability Beginning balance Ending balance Indefinite Lived Intangible Accumulated Amortization Indefinite Lived Intangible Accumulated Amortization Research, Collaboration and Licensing Agreements Collaborative Arrangement Disclosure [Text Block] Options granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Cash Cash [Member] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Debt securities, unrealized gain (loss) Debt Securities, Available-for-Sale, Unrealized Gain (Loss), Maturity, Allocated and Single Maturity Date, After Year One Through Three Debt Securities, Available-for-Sale, Unrealized Gain (Loss), Maturity, Allocated and Single Maturity Date, After Year One Through Three Research and License Agreement Research and License Agreement [Member] Research and license agreement. Enactment of new tax laws Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent Proceeds from marketable securities Proceeds from Sale and Maturity of Marketable Securities Income Tax Disclosure [Line Items] Income Tax Disclosure [Line Items] Income Tax Disclosure [Line Items] Balance, beginning of year Balance, end of year Unrecognized Tax Benefits Weighted-average common stock outstanding (note 4): Weighted Average Number of Shares Outstanding, Diluted [Abstract] Accounts payable and accrued liabilities (note 9) Total Accounts Payable and Accrued Liabilities, Current Other Commitments [Table] Other Commitments [Table] Leases Lessee, Operating Leases [Text Block] Net cash (used in) / provided by financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Weighted-average grant date fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Measure: Measure [Axis] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Issuance of common stock upon vesting of RSUs (note 10e) Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Change during the period Indefinite-Lived Intangible Assets, Period Increase (Decrease) Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Entity Tax Identification Number Entity Tax Identification Number SR&ED Tax Credits Effective Income Tax Rate Reconciliation, Tax Credit, Percent Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Trade payables Accounts Payable, Trade, Current Zymeworks BC Inc Zymeworks BC Inc [Member] Zymeworks BC Inc Total Liabilities, Other than Long-Term Debt, Noncurrent Common shares, issued (in shares) Common Stock, Shares, Issued Aggregate intrinsic value ($) Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value Operating leases Operating Lease, Weighted Average Remaining Lease Term IPR&D and Goodwill Goodwill and Intangible Assets Disclosure [Text Block] Current tax provision: Current Federal, State and Local, Tax Expense (Benefit) [Abstract] Entity Public Float Entity Public Float Number of remaining antibody clinical trials Number Of Remaining Antibody Clinical Trials Number Of Remaining Antibody Clinical Trials Trading Arrangement: Trading Arrangement [Axis] Income taxes payable Increase (Decrease) in Income Taxes Payable Total Shareholder Return Amount Total Shareholder Return Amount Security Exchange Name Security Exchange Name Income taxes, net of amounts refunded Income Tax Paid, Foreign, after Refund Received Other Effective Income Tax Rate Reconciliation, Cross-Border, Other, Percent Fair value of consideration allocated to a group of contracts that were considered as a single contract Fair Value Of Consideration Allocated, Group Of Contracts Fair value of consideration allocated to a group of contracts that were considered as a single contract. Non-taxable or non-deductible items Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount Acquisition of property and equipment and intangible assets in accounts payable and accrued liabilities Capital Expenditures Incurred but Not yet Paid Short-term marketable securities (note 5) Debt Securities, Available-for-Sale, Excluding Accrued Interest, Current Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Operating expenses: Operating Expenses [Abstract] Statement [Line Items] Statement [Line Items] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents Cash and Cash Equivalent Subsequent Event [Line Items] Subsequent Event [Line Items] Research Tax Credit Carryforward Research Tax Credit Carryforward [Member] Number of additional shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Deferred income tax expense (recovery) (note 13) Increase (Decrease) in Deferred Income Taxes Common stock Common Stock [Member] Net change in cash and cash equivalents Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Change in fair value of investments in equity instruments Unrealized Gain (Loss) on Investments Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] GlaxoSmithKline Intellectual Property Development Ltd. (“GSK”): GSK [Member] GSK Statistical Measurement [Domain] Statistical Measurement [Domain] Debt securities, available-for-sale, amortized cost, excluding accrued interest, before allowance for credit loss Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss Number of license options exercised Number Of License Options Exercised Number Of License Options Exercised Other Income (Expense), net Other Income and Other Expense Disclosure [Text Block] Leases [Abstract] Leases [Abstract] Gross increases related to prior year tax positions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Schedule of Other Long-Term Liabilities Other Noncurrent Liabilities [Table Text Block] Interest income Interest Income (Expense), Nonoperating Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Warrants outstanding (in shares) Class of Warrant or Right, Outstanding Basic (in dollars per share) Net loss per common share – basic (in dollars per share) Earnings Per Share, Basic Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Number of common shares reserved for issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Schedule of Revenue Recognized from Strategic Partnerships Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Changes in unrecognized tax benefits Effective Income Tax Rate Reconciliation, Tax Contingency, Percent Gross deferred tax assets Deferred Tax Assets, Gross Schedule of Segment Reporting Information, by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Deferred tax provision: Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Schedule of Marketable Securities Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Other general and administrative expense Other General and Administrative Expense Research and Development Costs Research and Development Expense, Policy [Policy Text Block] Upfront Fee Upfront Fee [Member] Upfront Fee Excise tax on repurchase of common stock Excise tax on share repurchases Share Repurchase Program, Excise Tax Compensation charge Share-based payment arrangement, expense Stock-based compensation expense Share-Based Payment Arrangement, Expense Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Current assets: Assets, Current [Abstract] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Total liabilities and stockholders’ equity Liabilities and Equity Foreign Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Number of Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Accumulated Amortization Indefinite-lived Intangible Assets Accumulated Amortization [Roll Forward] Indefinite-lived Intangible Assets Accumulated Amortization Other Deferred Tax Assets, Other General and administrative expense General and Administrative Expense [Member] Accounting Policies [Abstract] Accounting Policies [Abstract] Zanidatamab Zymeworks Zanidatamab Inc. [Member] Zymeworks Zanidatamab Inc. Schedule of Maturities of Operating Lease Liabilities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Commission expense on share repurchases Share Repurchase Program, Commission Expense Share Repurchase Program, Commission Expense Concentration Risk Type [Domain] Concentration Risk Type [Domain] Pay vs Performance Disclosure [Line Items] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Total operating lease liabilities Total operating lease liabilities Operating Lease, Liability Thereafter Lessee, Operating Lease, Liability, to be Paid, after Rolling Year Five Platform Technology Transfer and License Agreement Platform Technology Transfer and License Agreement [Member] Platform technology transfer and license agreement. Financial liabilities measured at fair value Financial Liabilities Fair Value Disclosure Option Exercise Fee Option Exercise Fee [Member] Option Exercise Fee [Member] Other long-term liabilities (note 9) Other Liabilities, Noncurrent Maximum exercise fees and milestone payments Collaborative Arrangement, Maximum Exercise Fees and Milestone Payments Collaborative Arrangement, Maximum Exercise Fees and Milestone Payments Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Goodwill, impairment loss Goodwill, Impairment Loss Statement of Cash Flows [Abstract] Company Selected Measure Amount Company Selected Measure Amount Other drug supply Drug Supply [Member] Drug Supply Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Expired (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Disposal Group Name [Domain] Disposal Group Name [Domain] Name Measure Name Royalty agreement term Royalty Agreement Term Royalty agreement term. Schedule of Loss Before Provision for Income Taxes Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Debt securities, fair value Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Secured Debt Secured Debt [Member] Number of operating programs Number Of Operating Programs Number Of Operating Programs Deferred tax liability (note 13)  Deferred tax liabilities Deferred Income Tax Liabilities, Net Non-capital losses carried forward Deferred Tax Assets Non-Capital Loss Carry Forwards Deferred Tax Assets Non-Capital Loss Carry Forwards 1 to 2 years Lessee, Operating Lease, Liability, to be Paid, Rolling Year Two Milestone revenue Milestone Revenue [Member] Milestone Revenue Warrants exercised during period (in shares) Warrants Exercised During Period Warrants Exercised During Period Short-term marketable securities: Available-for-Sale Securities, Debt Maturities [Abstract] Long-term Debt Long-Term Debt Legal Entity [Axis] Legal Entity [Axis] Total assets Assets 2026 Finite-Lived Intangible Asset, Expected Amortization, Year One Vested and settled (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Geographical [Domain] Geographical [Domain] Schedule of Estimated Useful Lives Schedule Of Property Plant And Equipment Estimated Useful Lives [Table Text Block] Schedule Of Property Plant And Equipment Estimated Useful Lives [Table Text Block]. Income Taxes Income Tax, Policy [Policy Text Block] Cash flows from operating activities: Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Drug supply for ongoing studies Drug Supply For Ongoing Studies [Member] Drug Supply For Ongoing Studies Warrants issued price per pre funded warrant (in dollars per share) Warrants Issued, Price Per Pre Funded Warrant Warrants issued price per pre funded warrant. Concentration Risk Type [Axis] Concentration Risk Type [Axis] Total shares authorized (in shares) All Classes Of Stock, Shares Authorized All Classes Of Stock, Shares Authorized Options granted under original plan exercisable period Share Based Compensation Arrangement By Share Based Payment Award Exercisable Period Share Based Compensation Arrangement By Share Based Payment Award Exercisable Period Research and development Research and Development Expense (Excluding Acquired in Process Cost) Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Leased assets obtained in exchange for operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Debt Securities, Available-for-Sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Level 2 Fair Value, Inputs, Level 2 [Member] Document Financial Statement Error Correction [Flag] Document Financial Statement Error Correction [Flag] State & local income tax, net of federal income tax effect Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Business Combination [Domain] Business Combination [Domain] Acquired Indefinite-lived Intangible Assets [Line Items] Intangible Asset, Acquired, Indefinite-Lived [Line Items] Schedule of Income Tax Expense Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] PEO PEO [Member] Supplemental disclosure of non-cash investing and finance items: Noncash Investing and Financing Items [Abstract] United States UNITED STATES Changes in non-cash operating working capital: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Changes in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Property and equipment Deferred Tax Liabilities, Property, Plant and Equipment Accumulated deficit Retained Earnings [Member] Income Tax Jurisdiction [Axis] Income Tax Jurisdiction [Axis] Cash and cash equivalents, beginning of year Cash and cash equivalents, end of year Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Income Statement [Abstract] Royalty percentage earned from sales of product (up to) Revenue, Remaining Performance Obligation, Variable Consideration, Royalty Percentage Royalty percentage earned from product sales. Purchases of marketable securities Payments to Acquire Marketable Securities Sale of Stock [Domain] Sale of Stock [Domain] Zanidatamab zovodotin Zanidatamab zovodotin [Member] Zanidatamab zovodotin Product and Service [Domain] Product and Service [Domain] Exchangeable stock, shares issued (in shares) Exchangeable Shares, Issued Exchangeable Shares, Issued Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Deferred financing fees Payments Of Deferred Financing Fees The amount of costs incurred as part of equity financing transactions that have been paid. City Area Code City Area Code Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Number of common shares issued (in shares) Redomicile Transaction, Number Of Shares Issued Redomicile Transaction, Number Of Shares Issued Cash, Cash Equivalents and Marketable Securities Investment [Text Block] United States of America, Dollars United States of America, Dollars Net deferred tax (liabilities) assets Deferred Tax Liabilities, Net Cash flows from investing activities: Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Issuance of common stock for retracted exchangeable shares Conversion of Stock, Amount Converted General and administrative General and Administrative Expense Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] License Agreements Research Collaborations And Development Agreements [Abstract] License Agreements Research Collaborations And Development Agreements [Abstract] License Agreements Research Collaborations And Development Agreements Johnson & Johnson Innovative Medicine (previously known as Janssen Biotech, Inc.) (“J&J”): Johnson and Johnson Innovative Medicine [Member] Johnson and Johnson Innovative Medicine Operating lease expense Lease, Cost Goodwill (note 6) Goodwill Schedule of Cost Components of Operating Leases Lease, Cost [Table Text Block] Federal Deferred Federal Income Tax Expense (Benefit) Unrecognized Tax Benefits [Roll Forward] Unrecognized Tax Benefits [Roll Forward] Auditor Name Auditor Name Stock Based Compensation Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount Guaranteed investment certificates (“GICs”) and mutual funds GICs and mutual funds Guaranteed Investment Contract [Member] Nature of Operations Nature of Operations [Text Block] Supplemental cash flow information: Supplemental Cash Flow Information [Abstract] Audit Information [Abstract] Audit Information Treasury stock payable Treasury Stock Payable Treasury Stock Payable Other Performance Measure, Amount Other Performance Measure, Amount Weighted- Average Exercise Price ($) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Deferred Tax Asset [Domain] Deferred Tax Asset [Domain] $ Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract] Credit Concentration Risk Credit Concentration Risk [Member] Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Leases Lessee, Finance Leases [Text Block] Additional paid-in capital Additional Paid in Capital, Common Stock Effect of Change in Accounting Estimate, Type [Axis] Effect of Change in Accounting Estimate, Type [Axis] Entity [Domain] Entity [Domain] Net cash provided by / (used in) investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Document Fiscal Year Focus Document Fiscal Year Focus Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Operating lease right-of-use assets (note 14) Operating Lease, Right-of-Use Asset Effective Income Tax Rate Effective Income Tax Rate Reconciliation, Percent Operating lease expense Operating Lease, Cost Gross decreases to tax positions in prior periods Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Software Computer software Computer Software, Intangible Asset [Member] Nonvested award, cost not yet recognized, period for recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Issuance of common stock on exercise of stock options (note 10e) (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Less: valuation allowance Deferred Tax Assets, Valuation Allowance Liability Classified Stock Options Liability Classified Stock Options [Member] Liability classified stock options. Building Building [Member] Business Segments Segment Reporting Disclosure [Text Block] U.S. Treasury notes U.S. Treasury notes US Treasury Securities [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Federal Current Federal Tax Expense (Benefit) Other Commitments [Line Items] Other Commitments [Line Items] Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] 2024 Repurchase Program Repurchase Program, 2024 [Member] Repurchase Program, 2024 Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Contingent liability Business Combination, Contingent Consideration, Liability Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Leases Lessee, Leases [Policy Text Block] Amortization of intangible assets (note 8) Amortization expense on intangible assets Amortization of Intangible Assets Exchangeable shares, shares outstanding (in shares) Exchangeable Shares, Outstanding Exchangeable Shares, Outstanding Deferred tax asset (note 13) Deferred Income Tax Assets, Net Percentage of royalty reduction Percentage of Royalty Reduction Percentage of Royalty Reduction Depreciation and amortization Depreciation, Depletion and Amortization Net proceeds from issuance Sale of Stock, Consideration Received on Transaction Number of antibody clinical trials initiated Number Of Antibody Clinical Trials Initiated Number Of Antibody Clinical Trials Initiated Reportable Segment Reportable Segment [Member] Reportable Segment Tax rate differential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Total finance lease liabilities Finance Lease, Liability Arrangement Duration Trading Arrangement Duration Segments [Axis] Segments [Axis] Local Phone Number Local Phone Number Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Assets Assets [Abstract] Intangible assets, net Finite-Lived Intangible Asset, Expected Amortization Finite-Lived Intangible Asset, Expected Amortization Underlying Security Market Price Change Underlying Security Market Price Change, Percent Debt Instrument [Axis] Debt Instrument [Axis] Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Stockholders’ equity: Equity, Attributable to Parent [Abstract] Treasury stock repurchased value Approximate value of shares purchased Treasury Stock, Value, Acquired, Cost Method Computer hardware Computer Hardware [Member] Computer Hardware [Member] Long-term portion of operating lease liability (note 14) Long-term portion Operating Lease, Liability, Noncurrent Entity Voluntary Filers Entity Voluntary Filers Contract assets and liabilities Contract Assets And Contract Liabilities [Policy Text Block] Contract assets and contract liabilities. 2 to 3 years Lessee, Operating Lease, Liability, to be Paid, Rolling Year Three License and Milestone Payments License and Milestone Payments [Member] License and milestone payments [member] Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Entity Registrant Name Entity Registrant Name Collaborative Arrangement Collaborative Arrangement [Member] Debt securities, unrealized gain (loss) Debt Securities, Available-for-Sale, Unrealized Gain (Loss), Maturity, Allocated and Single Maturity Date, After Year Three Through Four Debt Securities, Available-for-Sale, Unrealized Gain (Loss), Maturity, Allocated and Single Maturity Date, After Year Three Through Four Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Within 1 year Lessee, Operating Lease, Liability, to be Paid, Next Rolling 12 Months Employees Stock Purchase Plan Employees Stock Purchase Plan [Member] Employees Stock Purchase Plan [Member] Investment Tax Credit Carryforward Investment Tax Credit Carryforward [Member] Government Grants and Credits Government Grants And Tax Credits [Policy Text Block] Government grants and tax credits. Outside basis difference in foreign subsidiary Deferred Tax Liabilities, Outside Basis Difference Deferred Tax Liabilities, Outside Basis Difference Assets measured at fair value Assets, Fair Value Disclosure Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted Number of operating segments Number of Operating Segments Liquidity Risk Liquidity Risk, Policy [Policy Text Block] Liquidity Risk, Policy Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Kairos Acquisition Kairos Acquisition [Member] Kairos Acquisition Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Schedule of Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Restatement Determination Date: Restatement Determination Date [Axis] Foreign Deferred Foreign Income Tax Expense (Benefit) Accounts Receivable Accounts Receivable [Member] Number of reporting units Number of Reporting Units Issuance of common stock through employee stock purchase plan (note 10f) Proceeds from Issuance of Shares Under Employee Share Purchase Plan Amount of cash inflow from issuance of shares under share-based compensation arrangement. Issuance includes, but is not limited to, employee share purchase plan. License And Collaboration Agreement License And Collaboration Agreement [Member] License And Collaboration Agreement All Currencies [Domain] All Currencies [Domain] Enactment of new tax laws Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount Name Trading Arrangement, Individual Name Number of options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward] Schedule Of Accounting Policies [Line Items] Schedule Of Accounting Policies [Line Items] Schedule of accounting policies. Face amount Debt Instrument, Face Amount Temporary Equity, by Class of Stock [Table] Temporary Equity, by Class of Stock [Table] Property and equipment Deferred Tax Assets, Property, Plant and Equipment Collaborative arrangement, royalty percentage Collaborative Arrangement, Royalty Percentage Collaborative Arrangement, Royalty Percentage Share Repurchase Program [Axis] Share Repurchase Program [Axis] Preferred stock Preferred Stock [Member] Name Awards Close in Time to MNPI Disclosures, Individual Name Outstanding, at beginning of period (in dollars per shares) Outstanding, at end of period (in dollars per shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Buy down payment Collaborative Arrangement, Buy Down Payment Collaborative Arrangement, Buy Down Payment Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Other Other Accrued Liabilities, Noncurrent Issuance of common stock upon exercise of pre-funded warrants (note 10d) Stock Issued During Period, Value, Conversion of Convertible Securities Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Aggregate intrinsic vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Private placement for issuance of common stock (note 10a and 10d) Stock Issued During Period, Value, Private Placement Stock Issued During Period, Value, Private Placement Foreign Tax Jurisdiction [Member] Foreign Tax Jurisdiction [Member] Auditor Firm ID Auditor Firm ID Segments [Domain] Segments [Domain] Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Axis] Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Warrants issued to purchase shares (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Commercial and Development Milestones Commercial and Development Milestones [Member] Commercial and Development Milestones [Member] Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Net income (loss) per share Earnings Per Share, Policy [Policy Text Block] Milestone revenue Performance Milestone [Member] Performance Milestone [Member] Janssen Biotech, Inc. Janssen [Member] Janssen [Member] Preferred shares, $0.00001 par value; 100,000,000 authorized shares of preferred stock, out of which, one share of preferred stock is a share of Special Voting Preferred Stock and outstanding as of December 31, 2025 and December 31, 2024 (note 10b). Preferred Stock, Value, Issued Number of antibody development deprioritized Number Of Antibody Development Deprioritized Number Of Antibody Development Deprioritized All Executive Categories All Executive Categories [Member] Schedule of Significant Components of the Deferred Income Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Common shares, $0.00001 par value; 900,000,000 authorized shares of common stock at December 31, 2025 and December 31, 2024 (74,638,413 and 68,964,319 shares issued and outstanding at December 31, 2025 and 2024, respectively (note 10b). Common Stock, Value, Issued Commitments and contingencies (note 15) Commitments and Contingencies Options forfeited and cancelled (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value Business Combination [Axis] Business Combination [Axis] Maximum exposure to credit risk for accounts receivable Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure Debt securities, unrealized gain (loss) Debt Securities, Available-for-Sale, Unrealized Gain (Loss), Maturity, Allocated and Single Maturity Date, Year One Debt Securities, Available-for-Sale, Unrealized Gain (Loss), Maturity, Allocated and Single Maturity Date, Year One Schedule of Non-Vested Stock Option Activity Schedule of Nonvested Share Activity [Table Text Block] Operating lease liabilities Increase Decrease in Operating Lease Liabilities Increase decrease in operating lease liabilities. Recent Accounting Pronouncements Accounting Standards Update and Change in Accounting Principle [Text Block] Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag Impairment Of Intangible Asset, Indefinite-Lived, Excluding Goodwill, Statement Of Income Or Comprehensive Income, Extensible Enumeration, Not Disclosed Flag PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Scenario [Axis] Scenario [Axis] Schedule of Reconciliation of Beginning and Ending Amounts of Unrecognized Tax Benefits Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Bispecific Antibodies Bispecific Antibodies [Member] Bispecific Antibodies Proceeds from issuance of common stock under at-the-market program and from public offerings, net of issuance costs (notes 10a) Proceeds from Issuance of Common Stock All Individuals All Individuals [Member] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Acquisition of property and equipment Payments to Acquire Property, Plant, and Equipment Name Forgone Recovery, Individual Name Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Glaxo Smith Kline Intellectual Property Development Ltd Glaxo SmithKline Intellectual Property Development Ltd [Member] Glaxo smith kline intellectual property development. Issuance of common stock on exercise of stock options (note 10e) Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Shares granted with respect to maximum fixed amount equal, percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum Percentage of discounted purchase price of average market price Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Private Placement Private Placement [Member] ZW171 ZW171 [Member] ZW171 Liability at the beginning of the period Liability at end of the period Contingent Consideration Liability Fair Value Disclosure Contingent Consideration Liability Fair Value Disclosure Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Intangible Asset, Finite-Lived [Table] Intangible Asset, Finite-Lived [Table] Change during the period Indefinite-Lived Intangible Assets Acquired Geographical [Axis] Geographical [Axis] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Schedule of Balance Sheet Classification of Lease Liabilities Schedule of Lease Liabilities Classification [Table Text Block] Schedule of lease liabilities classification. Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Foreign exchange (loss) gain Gain (Loss), Foreign Currency Transaction, before Tax Net Indefinite-Lived Intangible Assets [Roll Forward] Collaboration agreement expense Collaboration Agreement Expense Collaboration Agreement Expense Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Arrangement Other than Collaborative Arrangement Other than Collaborative [Member] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Title of 12(b) Security Title of 12(b) Security Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Debt securities, amortized cost Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, After Year One Through Three Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, After Year One Through Three Total lease liabilities Lease Liability Lease Liability Change in recognition and measurement of tax positions Effective Income Tax Rate Reconciliation, Change In Recognition And Measurement Of Tax Positions, Amount Income tax reconciliation change in recognition and measurement of tax positions. Pre-Funded Warrant Pre-Funded Warrant [Member] Pre-Funded Warrant [Member] Net loss per common share (note 4): Earnings Per Share [Abstract] Issuance of common stock for retracted exchangeable shares (in shares) Conversion of Stock, Shares Converted Inducement Plan Inducement Plan [Member] Inducement Plan Other (expense) income, net (note 12) Total other income, net Nonoperating Income (Expense) Jazz: Jazz [Member] Jazz Foreign Base Company Income Effective Income Tax Rate Reconciliation, FDII, Percent Tax credit carryforward, amount subject to expiration Tax Credit Carryforward, Amount Deferred revenue and other consideration Increase (Decrease) in Contract with Customer, Liability Investments, fair value Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Through Four Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Through Four Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures Operating lease liability Deferred Tax Assets Operating Lease Liability Deferred tax assets, operating lease liability. Treasury stock repurchased (in shares) Treasury Stock, Shares, Acquired Eligible to Receive Scenario, Plan [Member] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Percentage interest in subsidiary sold Disposal Group, Subsidiary, Ownership Interest Sold Disposal Group, Subsidiary, Ownership Interest Sold Award Timing Disclosures [Line Items] Renewal term Lessee, Operating Lease, Renewal Term Vested and settled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised Impairment on IPR&D (note 6) Impairment of acquired IPR&D (note 6) Impairment on acquired IPR&D Impairment on IPR&D (note 6) Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Writeoff Other research and development expense Other Research and Development Expense Accrued research and development expenses Accrued Research Expenses Current Accrued research expenses, current. Stockholders' Equity Equity [Text Block] Stock-Based Compensation Stock Based Compensation [Policy Text Block] Stock Based Compensation. State Deferred State and Local Income Tax Expense (Benefit) Credit note for amendment of program Credit for Program Amendments [Member] Credit for Program Amendments Net loss Net (loss) income Net loss Net Income (Loss) Attributable to Parent Subsequent Event [Table] Subsequent Event [Table] Operating lease liabilities: Operating Lease, Liability [Abstract] Construction in progress Construction in Progress [Member] Schedule of Effective Income Tax Rate Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Other Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Net monetary liabilities denominated in foreign currency Net Monetary Liabilities Denominated In Foreign Currency Net Monetary Liabilities Denominated In Foreign Currency Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Purchases of common stock for retirement (note 10c) Payments for Repurchase of Common Stock Adoption Date Trading Arrangement Adoption Date Contract assets Contract with Customer, Asset, after Allowance for Credit Loss Total amount contributed by ESPP participants Contributions To Employee Share Purchase Plan contributions to employee share purchase plan. Customer [Axis] Customer [Axis] Loss from operations Segment loss Operating Income (Loss) Development support payments Research Support Payments And Other Service [Member] Research support payments and other [member] Accumulated deficit Retained Earnings (Accumulated Deficit) Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Change during the period Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill) Unrealized Gain (Loss) Debt Securities, Available-for-Sale, Unrealized Gain (Loss), Maturity, Allocated and Single Maturity Date, After Year One Through Four Debt Securities, Available-for-Sale, Unrealized Gain (Loss), Maturity, Allocated and Single Maturity Date, After Year One Through Four Class of Stock [Axis] Class of Stock [Axis] 2023 ATM Financing 2023 ATM Financing [Member] 2023 ATM Financing Subsequent Event Type [Domain] Subsequent Event Type [Domain] Other Effective Income Tax Rate Reconciliation, Cross-Border, Other, Amount Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Other Deferred Tax Liabilities, Other Payables and Accruals [Abstract] Payables and Accruals [Abstract] Other Other Nonoperating Income (Expense) Statement [Table] Statement [Table] Share issuance costs Deferred Tax Assets Share Issue Costs Deferred tax assets share issue costs. Deferred income tax (expense) recovery Deferred Income Tax Expense (Benefit) Gross decreases due to statute of limitations lapse Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Cash flows from financing activities: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Non-taxable or non-deductible items Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent All other foreign Foreign Tax Jurisdiction, Other [Member] Beginning balance (in shares) Ending balance (in shares) Shares, Issued Contract liabilities Contract with Customer, Liability Exchangeable shares, no par value, 553,184 issued and outstanding shares at December 31, 2025 (December 31, 2024: 570,637) (note 10b). Exchangeable Shares, Value, Issued Exchangeable Shares, Value, Issued Finance lease liability (note 14) Long-term portion included in other long-term liabilities Finance Lease, Liability, Noncurrent All Adjustments to Compensation All Adjustments to Compensation [Member] Purchase and retirement of common stock (10c) (in shares) Retirement of treasury stock (in shares) Treasury Stock, Shares, Retired Amendment Flag Amendment Flag U.S Dollar Under the New Option Stock Plan U S dollars under the New Stock Option Plan [Member] Us dollars under the new stock option plan. Share issued, price per share (in dollars per share) Sale of Stock, Price Per Share Termination Date Trading Arrangement Termination Date Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Discount rate Operating Lease, Weighted Average Discount Rate, Percent Schedule of Stock Options Granted Share-Based Payment Arrangement, Option, Activity [Table Text Block] Schedule of Assets Measured at Fair Value on a Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Unrecognized tax benefits that would impact effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Schedule of Net (Loss) Income per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Subsequent Events [Abstract] Subsequent Events [Abstract] Segment Reporting [Abstract] Options vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares Other income: Nonoperating Income (Expense) [Abstract] Scenario [Domain] Scenario [Domain] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Common stock, par value per share (in dollars per share) Common Stock, Par or Stated Value Per Share Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Three Finite-Lived Intangible Asset, Expected Amortization, after Year Three Granted (in shares) Options granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Effect of cross-border laws Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Amount License Agreement License Agreement Terms [Member] Debt securities, unrealized gain (loss) Debt Securities, Available-for-Sale, Unrealized Gain (Loss) Other comprehensive income (loss): Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent, Parenthetical Disclosure [Abstract] Use of Estimates Use of Estimates, Policy [Policy Text Block] Daiichi Sankyo, Co., Ltd. (“Daiichi Sankyo”): Daiichi Sankyo, Co., Ltd [Member] Daiichi sankyo, co., ltd. Patents and Intellectual Property Costs Patents And Intellectual Property Costs [Policy Text Block] Patents and intellectual property costs policy. Subsequent event Subsequent Events [Text Block] Insider Trading Arrangements [Line Items] Issuance of common shares on exercise of warrants (note 10) Proceeds from Issuance of Warrants Forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Long-term marketable securities: Debt Securities, Available-for-Sale, Amortized Cost [Abstract] Number of RSUs Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Total liabilities Liabilities Currency [Axis] Currency [Axis] Provincial tax rate differential Effective Income Tax Rate Reconciliation, Foreign Income Provincial Tax Rate Differential, Amount Effective Income Tax Rate Reconciliation, Foreign Income Provincial Tax Rate Differential, Amount Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Gross increases to current period tax positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Expense for other preclinical and research programs Other Preclinical And Research Programs [Member] Other Preclinical And Research Programs Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Derivative Liability Roll Forward [Roll Forward] Derivative Liability Roll Forward [Roll Forward] Derivative Liability Roll Forward Income Tax Disclosure [Table] Income Tax Disclosure [Table] Income Tax Disclosure [Table] Non-Recourse Secured Term Loan Non-Recourse Secured Term Loan [Member] Non-Recourse Secured Term Loan Issuance of common stock in connection with At-The-Market ("ATM") sale (note 10a) Stock Issued During Period, Value, New Issues Termination of long-term facility lease in Seattle, net Operating Lease Termination Operating Lease Termination Counterparty Name [Axis] Counterparty Name [Axis] Schedule of RSU Activity Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Non-NEOs Non-NEOs [Member] Corporate debt securities Corporate Debt Securities [Member] Milestone and Other Payments Milestone and Other Payments [Member] Milestone and other payments [member] Accounts Payable and Accrued Liabilities